A versatile one-step CRISPR-Cas9 based approach to plasmid-curing by Lauritsen, Ida et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
A versatile one-step CRISPR-Cas9 based approach to plasmid-curing
Lauritsen, Ida; Porse, Andreas; Sommer, Morten Otto Alexander; Nørholm, Morten
Published in:
Microbial Cell Factories
Link to article, DOI:
10.1186/s12934-017-0748-z
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Lauritsen, I., Porse, A., Sommer, M. O. A., & Nørholm, M. (2017). A versatile one-step CRISPR-Cas9 based
approach to plasmid-curing. Microbial Cell Factories, 16, [135]. DOI: 10.1186/s12934-017-0748-z
Lauritsen et al. Microb Cell Fact  (2017) 16:135 
DOI 10.1186/s12934-017-0748-z
TECHNICAL NOTES
A versatile one-step CRISPR-Cas9 based 
approach to plasmid-curing
Ida Lauritsen†, Andreas Porse†, Morten O. A. Sommer and Morten H. H. Nørholm* 
Abstract 
Background: Plasmids are widely used and essential tools in molecular biology. However, plasmids often impose a 
metabolic burden and are only temporarily useful for genetic engineering, bio-sensing and characterization purposes. 
While numerous techniques for genetic manipulation exist, a universal tool enabling rapid removal of plasmids from 
bacterial cells is lacking.
Results: Based on replicon abundance and sequence conservation analysis, we show that the vast majority of bacte-
rial cloning and expression vectors share sequence similarities that allow for broad CRISPR-Cas9 targeting. We have 
constructed a universal plasmid-curing system (pFREE) and developed a one-step protocol and PCR procedure that 
allow for identification of plasmid-free clones within 24 h. While the context of the targeted replicons affects effi-
ciency, we obtained curing efficiencies between 40 and 100% for the plasmids most widely used for expression and 
engineering purposes. By virtue of the CRISPR-Cas9 targeting, our platform is highly expandable and can be applied 
in a broad host context. We exemplify the wide applicability of our system in Gram-negative bacteria by demonstrat-
ing the successful application in both Escherichia coli and the promising cell factory chassis Pseudomonas putida.
Conclusion: As a fast and freely available plasmid-curing system, targeting virtually all vectors used for cloning and 
expression purposes, we believe that pFREE has the potential to eliminate the need for individualized vector suicide 
solutions in molecular biology. We envision the application of pFREE to be especially useful in methodologies involv-
ing multiple plasmids, used sequentially or simultaneously, which are becoming increasingly popular for genome 
editing or combinatorial pathway engineering.
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Background
Since their discovery in the early 1950s, plasmids have 
played a pivotal role in the advancement of molecular 
biology, and form the basis for DNA cloning and gene 
expression in modern biotechnology [1]. While the 
diversity and applications of cloning vectors have grown 
dramatically, the vector backbones used today are, for 
historical reasons, build upon a limited set of parts [2–6].
A central property of a plasmid is its replication 
machinery that determines the copy-number and ability 
of plasmids to co-exist [7]. One group of cloning vectors 
that display a relatively high copy-number is based on the 
ColE1-like replication machinery, including the pMB1 
replicon of pBR322 and its high-copy derivatives found in 
e.g. pUC18/19,  pBluescript® and pJET1.2® [5, 8]. All of 
the ColE1-derived replicons function via anti-sense RNA 
for replication control but are able to co-reside to some 
degree. This group of RNA-controlled ColE-like rep-
licons also contains the widely used p15A replicon that 
can stably exist together with ColE1-like plasmids and is 
maintained in fewer copies per cell [3, 9]. A large propor-
tion of naturally occurring plasmids replicate through the 
use of replication (Rep) proteins that act in a self-inhibi-
tory fashion to control plasmid copy-number [10]. These 
include the replicons of pBBR1, RK2 and RSF1010 that 
are found in cloning vectors and function in a broad host 
context [11]. Similarly, the Rep protein based pSC101 
vector was the first to be used for recombinant gene 
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expression, and is popular due to its relatively high sta-
bility in spite of a low copy-number (<8 copies per cell) 
along with the ability to co-exist with ColE1-like and 
p15A replicons [1, 12].
While techniques for transfer of plasmid DNA into 
many bacterial hosts are well established, obtaining 
plasmid-free cells still poses a significant challenge [13, 
14]. In genome and metabolic engineering, the intro-
duction of one or more plasmid-based genetic tools is 
often required, although a plasmid-free strain is even-
tually desired [15–18]. For example, sequential steps of 
plasmid-based genome editing, and the use of screening 
and characterization tools for strain engineering might 
involve multiple vectors that need removal prior to final 
application of the strain [17, 19].
Due to the high copy-number and intrinsic stability of 
modern cloning vectors, plasmid-curing is often tedious. 
Traditional methods for plasmid-curing are based on pro-
longed growth under stressful conditions, such as elevated 
temperature or the addition of DNA intercalating agents, 
to interfere with plasmid replication [14]. Other methods 
based on replicon-incompatibility exploit competition 
between identical replicons but require precise knowledge 
of the replication machinery of the target plasmid, as well 
as subsequent curing of the interfering plasmid [13, 20]. 
A considerable downside of the existing methods is the 
variable efficiency, time consumption, and the risk of accu-
mulating unwanted mutations due to prolonged growth 
regimes and the use of mutagenic curing agents [17, 21].
To accommodate the need for efficient removal of 
cloning vectors when needed, temperature sensitive 
plasmid-replicons have been developed [22]. However, 
the relatively large size, temperature restrictions, low 
copy-number and little variety of these vectors, compli-
cates cloning procedures and limits their application for 
multi-plasmid and broad-host purposes. Another way to 
facilitate the selection of plasmid-free clones is by incor-
porating a counter-selectable marker into the plasmid 
backbone [23]. Although this strategy allows for rapid 
identification of cells lacking the marker gene, these do 
not actively remove the plasmid and negative selection 
markers are prone to mutational escape and often have 
stringent requirements to the growth media and host 
background [23–25].
With the advent of CRISPR-Cas9 technology, mim-
icking the natural bacterial defense against plasmid and 
phage intruders, a powerful and flexible approach to 
precise DNA targeting is now available for a wide range 
of organisms [26, 27]. Although CRISPR-Cas9 has been 
applied for specific targeting of certain plasmid features, 
a generally applicable platform for quick and efficient 
curing of cloning vectors will constitute a highly useful 
tool in molecular biology [28].
Here we exploit the common origin of modern plasmid 
vectors to develop a broadly applicable CRISPR-Cas9-
based curing platform. We show that our system enables 
fast and efficient curing of all major plasmid replicons 
used in modern molecular biology laboratories and can 
be applied in a broad phylogenetic context.
Results
We first explored the distribution of cloning vector rep-
licons by performing a BLAST search of selected repli-
cons against all bacterial plasmids with full nucleotide 
sequences available in the Addgene plasmid reposi-
tory [29] (Fig.  1). The ColE1-like (including p15A) and 
pSC101 replicons accounted for 91% of the plasmids in 
the Addgene database. The vast majority of these plas-
mids belonged to the ColE1 family (86.4%), underlin-
ing the popularity of these vectors in molecular biology 
(Fig.  1). Surprisingly, a considerable fraction of vectors 
annotated with the pBBR1 and RK2 broad host-range 
replicons also contained full-sized ColE1-like replicon 
sequences. Including these redundant replicons in our 
calculations, a plasmid-curing system targeting the ColE1 
and pSC101 plasmid groups will cover 93.3% of the (at 
present 4657) bacterial vectors deposited in Addgene 
(Additional file 1: Figure S1).
Through sequence alignments of representative repli-
cons from each replicon-group, we identified highly con-
served regions between all ColE1-like replicons that were 
also shared with p15A (Fig. 2a). These regions were used 
to design CRISPR-Cas9-compatible guide RNA (gRNA) 
that, upon recognition by Cas9, target all ColE1-like and 
p15A vectors. Because the protein-based mechanism of 
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Fig. 1 Frequency of major replicons in bacterial cloning and 
expression vectors deposited to Addgene. A BLAST search was 
performed against all complete bacterial vector sequences (4657) 
in the Addgene database (Feb. 2017). ColE1-like plasmids include 
the closely related RNA-based replicons of ColE1, pBR322/pMB1, 
pUC18/19, pJET1.2®, colA and p15A
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pSC101 replication is fundamentally different from that 
of the ColE1-like replicons, we designed separate gRNA 
to facilitate curing of the pSC101-based vectors. To 
increase curing efficiency and counteract the potential 
for mutational escape, we included two gRNA targets for 
each replicon group (Table 1).
The four gRNAs were implemented as a CRISPR-array, 
along with the tracrRNA and Cas9-components and 
incorporated into a single vector containing all parts 
necessary to form the fully functional curing system 
designated “pFREE” (Fig.  2b). An important feature of 
a b
c
Fig. 2 a Selection of gRNA-targets based on conserved regions of popular replicon-families. Selected replicon sequences representing the RNAI 
and RNAII encoding part of ColE1 and the repA encoding part of pSC101 replicon groups, were aligned and gRNA was selected based on the 
degree of conservation (illustrated as the color intensity). The center part of repA was fully conserved and omitted in the depiction. The plasmid 
names in grey boxes are examples of vectors belonging to each replicon family. Two gRNAs were selected for each replicon group, and all four gRNAs 
were combined into a CRISPR-array (crArray). b Plasmid map of pFREE. The pFREE plasmid was constructed by inserting the crArray targeting the 
ColE1 and pSC101 replicons into a colA vector encoding Cas9 along with other essential modules for CRISPR-Cas9 activity such as trans-activating 
CRISPR RNA (trcrRNA). The gRNA array and Cas9 nuclease are controlled by the inducible rhamnose (PrhaBAD) and tetracycline (Ptet) promoters to 
ensure tight regulation of curing functionality. c One-step curing workflow using the pFREE system. The pFREE plasmid is transformed into a strain 
harboring the target plasmids for curing. After transformation recovery, cells from the recovered culture are transferred into medium with pFREE 
selection, 0.2% rhamnose and 200 ng/mL anhydrotetracycline (aTc) added. The system is induced overnight (O/N) to allow the cleavage of target 
plasmids (red and green respectively) by Cas9 (blue), guided by the gRNA expression from pFREE (black plasmid). The culture is plated on non-selec-
tive agar and cured cells can be identified by replicon PCR (Additional file 1: info S2) or by phenotypic screening e.g. antibiotic sensitivity
Table 1 Selected gRNAs and their target replicons
gRNA Sequence (5′ to 3′) Targeted replicon group
gRNA1 ATGAACTAGCGATTA
GTCGCTATGACTTAA
pSC101
gRNA2 AACCACACTAGAGAA
CATACTGGCTAAATA
pSC101
gRNA3 GGTTGGACTCAAGAC
GATAGTTACCGGATA
ColE1-like except colA
gRNA4 GGCGAAACCCGACAG
GACTATAAAGATACC
ColE1-like including colA (self-curing 
of pFREE)
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a plasmid-curing system is a suicide functionality that 
renders the resulting cells completely plasmid-free with-
out any additional incubation steps. The pFREE vector 
is based on the colA replicon that resembles ColE1-like 
replicons to some degree but colA is only recognized by 
one of the ColE1-targeting gRNAs. Due to the self-curing 
feature of pFREE, plasmid-curing can be done in a one-
step workflow directly after transformation of pFREE as 
outlined in Fig. 2c.
Quantification of curing efficiency
In order to test the efficiency of our plasmid-curing sys-
tem, we constructed three target plasmids by inserting 
gfp under control of a constitutive promoter into simi-
lar backbones of the pZ vector system [30]. These three 
plasmids differ only by their ColE1, p15A or pSC101 
replicons and are designated pZE-GFP, pZA-GFP and 
pZS-GFP. The curing efficiency was quantified at differ-
ent time points, and the loss of fluorescence reflected 
plasmid-curing of the gfp expressing vectors. The curing 
rates were comparable between the target plasmids and 
after 24 h the vast majority of all three populations were 
cured with 80–90% of the plated cells being plasmid-free 
(Fig. 3). Non-fluorescent cells were assessed for self-cur-
ing of the pFREE plasmid by kanamycin sensitivity, and 
no pFREE-carrying cells were detected after 24 h. These 
results clearly demonstrate effective plasmid-curing of 
vectors with ColE1, p15A and pSC101 replicons, targeted 
by the crArray of the pFREE system, and efficient self-
curing of the pFREE plasmid.
pFREE cures major cloning vector‑systems used in E. coli
Seven representatives of widely used cloning and expres-
sion vector systems were selected to demonstrate the 
general applicability of the pFREE system to cure com-
monly used vectors with similar replicons but vari-
able backbone content. The majority of these plasmids 
contained variations of ColE1 replicons including the 
pJET1.2®, pUC19 and  pBluescript® high copy-number 
variants as well as a pET-vector most commonly used for 
Fig. 3 Time course characterization of the pFREE plasmid-curing system. Curing of pZ-plasmids expressing GFP with either pSC101 (pZS-GFP, 
green), ColE1 (pZE-GFP, red) or p15A (pZA-GFP, blue) replicon. The solid lines indicate induced cultures with rhamnose (Rham) and anhydrotetra-
cycline (aTc), whereas the dashed lines refer to non-induced (Ø). Plating was performed at induction time (0) and 3, 7, 11 and 24 h after induction. 
Between 100 and 150 colony forming units (CFUs) were counted from each replicate and the ratio between fluorescent and non-fluorescent cells 
were determined. The percentage of plasmid-carrying cells is depicted. Of the non-fluorescent and tested cells, all had lost the pFREE plasmid after 
24 h. Data points represent mean value of three biological replicates with error-bars showing standard deviation. Representative LB agar plates for 
pZE-GFP with equal number of cells plated with cultures induced with rhamnose and aTc (top) and non-induced (Ø) (bottom) of the pFREE system 
after 24 h
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protein production. In addition, the low copy-number 
pSEVA471 [31] plasmid harboring a pSC101 replicon and 
the p15A-based pACYC-Duet-1 medium-copy plasmid 
was also included.
While the pSEVA471 and pACYC-Duet-1 plasmids 
were cured with similar efficiency to what was observed 
for the pZ plasmids (Figs. 3, 4), the ColE1-like replicons 
were cured with efficiencies ranging from 40 to 100%. 
These results exemplify that, although replicon con-
text does play a role, the pFREE system can be used for 
efficient curing of the most common commercial plas-
mid vectors with varying copy-numbers and auxiliary 
content.
One‑step curing of multiple plasmids
To improve the practical application of the pFREE system 
as a fast and simple curing system, we developed a one-
step workflow as displayed in Fig.  2c. Plasmid-curing is 
induced directly after pFREE-transformation and com-
pletely plasmid-free clones (without target and pFREE 
plasmids) can easily be detected either by phenotypic 
screening (e.g. antibiotic sensitivity) or faster by the set 
of universal replicon amplifying PCR oligonucleotides 
that we developed (Additional file 1: info S2). To test the 
one-step protocol and to evaluate the performance of the 
pFREE system for curing multiple plasmids simultane-
ously, we prepared a strain containing three compatible 
target plasmids. After transformation of pFREE into this 
strain, the target plasmids were cured directly from the 
transformation mix and plated on non-selective LB agar 
after overnight induction. From the tested cells, 80% were 
completely cured whereas 10% or less contained one or 
more plasmids and all cells had lost pFREE (Fig. 5).
Self‑curing dynamics of pFREE
To investigate the dynamics of the pFREE self-targeting 
feature, we quantified the self-curing efficiency of the 
pFREE plasmid over time. In the absence of plasmid 
selection, 90% of the cells were cured of pFREE after 7 h 
of induction whereas 65% of the cells were cured in the 
presence of plasmid selection (Additional file  1: Figure 
S2). After 10 h of pFREE induction, all cells were cured 
for pFREE regardless of the plasmid selection.
pFREE‑RK2: a temperature sensitive and broad host‑range 
version of pFREE
The curing efficiency of the pFREE system was between 
40 and 100% as depicted in Figs.  3 and 4. Due to the 
highly efficient self-curing of pFREE, we speculated that 
over-efficient self-targeting could be a bottleneck pre-
venting complete curing of the target plasmids. In that 
case, a system allowing self-curing to take place only after 
the target plasmid-curing has occurred, might increase 
duration of CRISPR expression and consequently the 
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Fig. 4 pFREE-mediated curing of selected widely used cloning 
vectors with either ColE1-like (red), pSC101 (green) or p15A (blue) 
replicons. 50 CFUs from each replicate of each target plasmid was 
checked for antibiotic sensitivity after 24 h of induction of the pFREE 
system. The percentage of plasmid-carrying cells is depicted. The 
pFREE plasmid was cured in all colonies tested. Curing of the target 
plasmids was verified by replicon PCR (Additional file 1: info S2). The 
bars represent mean value of three biological replicates with error-
bars showing standard deviation
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Fig. 5 Curing of multiple co-residing plasmids using the one-step 
transformation protocol depicted in Fig. 2c. The pFREE plasmid was 
transformed into a strain harboring the same three pZ plasmids as 
used in Fig. 3. After recovery, plasmid-curing with the pFREE system 
was induced and cultures were plated after 24 h of induction. 50 
CFUs from each replicate were checked for antibiotic sensitivity on 
LB agar plates. The percentage of cells carrying 0, 1, 2, 3 (orange plas-
mids) or pFREE (black plasmid) is depicted. The bars represent mean 
value of three biological replicates with error-bars showing standard 
deviation
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curing efficiency. To compare the effect of self-curing 
mechanism and copy-number on curing outcomes, we 
designed a pFREE version with the temperature-sensi-
tive, low-copy RK2 replicon that replicates in a broad 
representation of Gram-negative bacteria [32] desig-
nated pFREE-RK2 (Additional file  1: Figure S3). The 
RK2 replicon is not targeted by the pFREE crArray, thus 
omitting the CRISPR-Cas9-based self-curing feature of 
the pFREE system but carries a trfA mutant that allows 
curing at elevated temperatures instead [33]. The cur-
ing efficiency of the pFREE-RK2 system was quantified 
in the same way as for pFREE and exhibited comparable 
curing efficiencies of 35–100% (Additional file 1: Figures 
S4, S5). The highly similar curing efficiencies observed 
for pFREE and pFREE-RK2, indicates that simultaneous 
self-curing and curing of target plasmid does not signifi-
cantly affect the overall curing efficiency of the system. 
Multi-plasmid curing by the one-step protocol was also 
tested for pFREE-RK2 and showed comparable efficiency 
(Additional file 1: Figure S6), demonstrating that a lower 
copy-number and fundamentally different mechanism 
of self-curing does not alter CRISPR-Cas9 targeting 
efficiency.
Curing in Pseudomonas putida
To demonstrate the versatility of our plasmid-curing sys-
tem in a broader phylogenetic context, we set out to test 
the pFREE-RK2 in an alternative host bacterium sup-
ported by the RK2 replicon. We chose the Gram-negative 
soil bacterium Pseudomonas putida as our model host 
due to its promise as a new and powerful chassis for 
metabolic engineering and production of fine chemicals 
[34]. Using the P. putida strain KT2440 harboring the 
gfp-expressing pSEVA441-GFP plasmid, we targeted the 
ColE1-based pRO1600/ColE1 fusion replicon without 
the need to change any components of the pFREE-RK2 
curing plasmid. After overnight induction of the curing 
system, approximately half of the P. putida population 
(53% SD  ±  5.1%, three biological replicates) was cured 
for pSEVA441-GFP, whereas no detectable curing was 
observed without pFREE-RK2. These results demonstrate 
that our CRISPR-based curing system can be applied in a 
broader host context and that CRISPR-Cas9 technology 
can be successfully applied in P. putida.
pFREE enables precise curing without off‑target effects
The curing functionality of pFREE is tightly regulated 
and the gRNAs were selected to avoid potential off-tar-
get effects of CRISPR-Cas9 expression [35]. However, to 
ensure that the curing activity of pFREE did not induce 
off-target effects, we whole-genome sequenced three 
individual isolates of E. coli and P. putida harboring 
pFREE or pFREE-RK2 respectively before and after the 
curing procedure. The sequencing results showed that 
24 h of induction with the pFREE system did not cause 
mutations (SNPs and small INDELS) or larger rearrange-
ments in the host genomes; confirming the orthogonality 
of pFREE in these hosts.
Discussion
Plasmids are fundamental in all aspects of molecular biol-
ogy due to their role as genetic scaffolds that are easy to 
modify and transfer between hosts. However, when plas-
mids carry functions that are only temporarily necessary, 
or a clean strain background is needed, limited options 
are currently available for efficient plasmid-curing of the 
most widely used cloning vectors in bacteria.
Existing methods for plasmid-curing are based on 
curing agents or incompatibility mediated plasmid dis-
placement [13, 20]. However, these methods require 
sequential rounds of growth in stressful or non-selective 
conditions to promote the appearance of plasmid-free 
segregants. Such methods increase the chance of accu-
mulating unwanted mutations and are time-consuming. 
Prior work has demonstrated that plasmids, traditionally 
considered incompatible can co-exist stably for multiple 
growth cycles [36], which only complicates incompatibil-
ity-based plasmid-curing further; especially for plasmids 
maintained at high copy-numbers.
To address this methodological bottleneck, we devel-
oped the pFREE system as a fast and simple one-step 
plasmid curing-method based on sequence conserva-
tion within replicon groups and CRISPR-Cas9-targeted 
plasmid cleavage. Using this system, curing of one or 
multiple target plasmids can be performed directly after 
transformation of the pFREE plasmid and cured cells 
can easily be screened for specific phenotypes (e.g. anti-
biotic resistance) or by the diagnostic PCR developed 
here (Additional file  1: info S2). In the absence of prior 
plasmid sequence information, the PCR based replicon 
identification protocol is also useful for replicon profiling 
prior to curing (Additional file 1: info S2).
Using the pFREE system, we cured both single and 
multiple plasmids with an efficiency of 40–100% (Figs. 3, 
4). We investigated the dynamics of the pFREE self-
curing feature and observed complete curing of pFREE 
already after 10  h with kanamycin added for pFREE 
selection. Although the inclusion of pFREE selection dur-
ing curing reduced the self-curing rate, and allows for the 
one-step transformation protocol, it also shows that cells 
that are actively cured during selective culturing are not 
necessarily killed (Additional file 1: Figure S2; Fig. 2c).
Such persistence may result from slower degradation 
of the resistance conferring aminoglycoside phospho-
transferase enzyme compared to the rate of plasmid-cur-
ing, or could be an effect of indirect resistance were the 
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antibiotic sensitive cells are protected by pFREE-carrying 
cells [37].
We first speculated that the highly efficient self-cur-
ing of pFREE was limiting the trans-curing efficiency 
of pFREE. However, similar curing efficiencies were 
observed when the self-targeted colA replicon was 
replaced with the temperature sensitive RK2 replicon 
(pFREE-RK2).
Differences in curing efficiencies were observed for 
the individual plasmids tested here; presumably caused 
by variations in copy-number, plasmid incompatibility 
or fitness constrains originating from other factors pre-
sent in the plasmid backbones. We did not observe a 
clear correlation between copy-number and curing effi-
ciency, with the extremely high copy vectors of pJET1.2®, 
 pBluescript® and pUC19 displaying curing efficiencies 
similar to the low and medium-copy-number pSEVA471 
and pACYC-Duet-1 (Fig. 4). Although the overall curing 
efficiency was similar between pFREE and pFREE-RK2, 
there were small differences in the relative efficiency 
against the different replicon families (Fig. 3; Additional 
file  1: Figure S4). Such differences, e.g. the higher effi-
ciency for curing of replicons more similar to the rep-
licon of the curing plasmid, could be a result of partial 
replicon incompatibility and might explain the higher 
loss of p15A and ColE1-like RNA-based replicons for 
pFREE when co-residing without induction of the cur-
ing system (Fig. 3; Additional file 1: Figure S4). Surpris-
ingly, the pBR322 plasmid was completely cured for both 
versions of pFREE, whereas the pET-Duet-1, carrying 
the exact same replicon, displayed the lowest curing effi-
ciency (40% cured) observed here; indicating a substan-
tial effect of auxiliary plasmid factors on plasmid stability 
(Fig. 4; Additional file 1: Figure S5). Such differences can 
be caused by factors such as resistance markers or other 
genetic cargo that affects plasmid persistence at the pop-
ulation level. The pBR322 is known to inflict a fitness cost 
on E. coli hosts due to the expression of the costly tetra-
cycline efflux pump encoded by tetA [38]. If a high fitness 
benefit of losing the plasmid exists, the expansion of the 
plasmid-free population will contribute exponentially to 
the observed plasmid loss and synergistically improve the 
curing outcome.
Mutations in target plasmids or in the CRISPR plat-
form of pFREE along with biological stochasticity could 
also explain the non-perfect curing of target plasmids by 
our system. CRISPR-Cas9 systems are widely used for 
genome-editing purposes, and other applications have 
shown similar susceptibility to small subpopulations of 
“escapers” that avoid targeting [39].
We developed the crArray encoded by pFREE to tar-
get replicons belonging to the ColE1/p15A and pSC101 
groups based on the distribution of replicons in bacterial 
vectors deposited in the Addgene database, which agreed 
with historical trends in cloning vector usage [1, 5, 9]. 
Additionally, we discovered that the selected gRNAs in 
pFREE indirectly target vectors with other replicons such 
as pBBR1 and RK2 due to redundant replicon sequences 
present in a high proportion of these backbones (Addi-
tional file 1: Figure S1). Although we target the majority 
of replicons used for routine cloning in E. coli there are 
exceptions within the broad host-range vectors and R6K 
(Additional file 1: Figure S1). The R6K replicon is primar-
ily used as a suicide vector and is of little relevance in a 
curing perspective [40]. Since the vast majority of plas-
mid vectors that are used belong to the ColE1-like, p15A 
or pSC101 replicon groups (Fig. 1), the chance of a tar-
get plasmid being covered by the pFREE system is high. 
Hence, less knowledge about the replicon group of target 
plasmids is needed prior to curing compared to incom-
patibility-based curing methods [13] and only a few colo-
nies will have to be screened to identify a cured variant.
Due to the broad functionality of the CRISPR-Cas9 
technology in a variety of organisms [27] the pFREE 
curing system has great potential as a universal plas-
mid-curing tool in bacteria, as shown here for both 
E. coli and P. putida, and can in theory be expanded to 
eukaryotic organisms such as yeast where plasmids are 
also employed [41]. With decreasing cost of nucleic acid 
synthesis, custom crArrays for targeting of other plas-
mids than the ones included here are easily implemented 
into the pFREE backbones. It is possible that a similar 
approach can be used clinically to combat the increasing 
medical burden of plasmid-encoded multidrug resistance 
in pathogenic bacteria. Although the diversity of natural 
plasmid replicons by far exceeds that of cloning vectors, 
the most endemic plasmid-families encoding virulence 
and antibiotic resistance factors do share conserved fea-
tures within their replication, stability, resistance and 
conjugation modules that could be targeted for future 
expansion of our plasmid-curing system [42, 43].
Conclusions
We show that all major replicons used for cloning and 
expression purposes share sequence features that allow 
for universal CRISPR-Cas9 targeting and use this infor-
mation to develop a fast and one-step plasmid-curing 
platform that allows for targeting of the major classes of 
vectors used in molecular biology. Using our curing pro-
tocol, we demonstrate efficient curing of major cloning 
and expression vectors in biotechnology and perform in-
depth characterization of the curing dynamics. To facili-
tate subsequent identification of plasmid-cured variants, 
we supply a set of universal primers that allow for rapid 
PCR screening directly from a culturing plate. Further-
more, we construct a temperature-sensitive and broad 
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host-range version of pFREE (pFREE-RK2) that provides 
an efficient curing solution for broad range of Gram-neg-
ative bacteria including the upcoming cell factory Pseu-
domonas putida.
Methods
Replicon prevalence and conservation analysis
Bioinformatic analysis was performed using the CLC 
Main Workbench (QIAGEN Bioinformatics) and R (ver-
sion 3.3.1) software. Replicons used in multiple sequence 
alignments and BLAST searches were downloaded 
from GenBank or Addgene. Sequences with the follow-
ing accession numbers were included as ColE1-like rep-
licons: ColE1 (GenBank NC_001371), pBR322/pMB1 
(GenBank J01749.1), pUC19 (Addgene plasmid #49793), 
pJET1.2® (GenBank EF694056.1), ColA (Addgene plas-
mid #73962). In addition, p15A and pSC101 replicons 
were included: p15A (GenBank V00309.1) and pSC101 
repA (GenBank K00042.1), temperature sensitive pSC101 
repA of pKD46 (GenBank AY048746) and pGRG36 
(GenBank DQ460223.1). For the BLAST analysis, the 
R6K (GenBank KX485333.1) and broad host-range rep-
licons of pBBR1 (GenBank U02374.1), trfA gene of RK2 
(GenBank U05774.1) and RSF1010 (GenBank M28829.1) 
were also included.
Multiple alignments were used to identify conserved 
regions in the selected replicon sequences. gRNA was 
selected based on broad conservation in replicons, as 
well as the absence of matches to proteobacterial chro-
mosomes in NCBIs RefSeq database; where at least four 
chromosomal mismatches were present for each gRNA 
sequence.
We downloaded all (4657) Addgene entries of bacterial 
plasmids where the full nucleotide sequence was acces-
sible from the search function at https://www.addgene.
org/ (accessed Feb. 2017). Replicon frequencies and 
positive gRNA hits were assessed using BLAST [44]. An 
e-value cutoff of 1e-130 was used for replicon BLAST 
and allowed proper classification according to database 
annotations. For gRNA BLAST searches, only hits with 
a perfect match to the query replicons were included as 
positive hits.
Plasmid construction
pFREE was constructed by amplification of the pMAZ-
SK backbone [18] using oligonucleotides 1 and 2. See 
Additional file  1: Table S3 for all plasmids and refer-
ences and Additional file  1: Table S4 for all oligonu-
cleotides used in this study. The crArray encodes four 
different gRNAs of 30 nts, separated by direct repeats 
of 36 nts. The crArray was constructed by PCR using 
two ultramer oligonucleotides 3 and 4 (size of 200 nts 
and 173  nts respectively) with an overlapping region 
of 72  nts mixed with the two uracil-containing oligo-
nucleotides 5 and 6, and cloned into the pMAZ-SK 
amplified PCR backbone by USER cloning as described 
previously [45]. Insertion of the tetratracycline repres-
sor (tetR) was performed by Gibson assembly as 
described elsewhere [46] with oligonucleotides 7 and 8 
for pMAZ-SK backbone amplification and tetR ampli-
fication from plasmid pZS4Int-tetR with oligonucleo-
tides 9 and 10. Oligonucleotides 11 and 12 were used 
to amplify the pFREE backbone and the Cas9 gene 
was amplified from pMA7CR_2.0 [18] with oligonu-
cleotides 13 and 14 and cloned into pFREE by Gibson 
assembly.
The temperature sensitive broad host-range version of 
pFREE (pFREE-RK2) was constructed by amplification 
of the temperature sensitive RK2 replicon from pSIM9 
[47] using oligonucleotides 15 and 16, including the trfA 
gene and oriV regions. The backbone from pFREE was 
amplified with oligonucleotides 17 and 18 to insert the 
RK2 replicon into the pFREE backbone via USER cloning 
[48]. Likewise, versions of pFREE and pFREE-RK2 with 
ampicillin, chloramphenicol and zeocin resistance genes 
were constructed and all pFREE constructs are available 
through Addgene.
Bacterial strains, media and growth conditions
Escherichia coli Top10 (Thermo Fisher Scientific, 
Waltham, MA, USA) was used for cloning and cur-
ing experiments. E. coli cultures were grown in lysog-
eny broth (LB) at 30  °C with shaking at 270  rpm. The 
antibiotics ampicillin (100  μg/mL), chloramphenicol 
(34 μg/mL), zeocin (100 μg/mL) and kanamycin (50 μg/
mL) were added when needed. crArray expression was 
induced with 0.2% l-rhamnose (w/v) and expression of 
Cas9 endonuclease was induced with 200  ng/mL anhy-
drotetracycline (aTc).
Time course curing dynamics of pFREE and pFREE‑RK2
Overnight cultures of E. coli Top10 harboring the pZA-
GFP, pZE-GFP or pZS-GFP plasmid respectively and 
pFREE or pFREE-RK2 were diluted 2000-fold in 10  mL 
LB broth containing 0.2% l-rhamnose, 200  ng/mL aTc 
and 50  μg/mL kanamycin. Cultures were grown from 
three randomly picked colonies. Time course assessment 
of curing efficiency was done by plating on non-selective 
LB agar. For each time-point, the ratio between fluores-
cent cells and non-fluorescent cells were determined 
by quantification of GFP-fluorescent colonies among 
100–150 CFUs from each plate. To assess self-curing of 
pFREE, at least 10 colonies were checked for growth on 
LB agar plates containing kanamycin (50 μg/mL).
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Curing of widely used cloning and expression vectors
The plasmids pET-Duet-1, pBR322, pJET1.2®, pUC19, 
pACYC-Duet-1, pSEVA471  pBluescript® and pSEVA441-
GFP were cured with the protocol described above. To 
test for plasmid-curing, individual colonies were checked 
for growth on LB agar plates containing the relevant anti-
biotic. Plasmid-curing was verified by replicon PCR with 
oligonucleotides S1, S2, S3, S4 and S5 (Additional file 1: 
info S2).
One‑step curing of multiple plasmids
Escherichia. coli Top10 strain harboring three (pZA-GFP, 
pZE-GFP and pZS-GFP) plasmids was grown in 5 mL LB 
containing antibiotics for plasmid selection. The culture 
was grown to an  OD600 of 0.3 and made electrocompe-
tent by three steps of washing in MilliQ water. 50 μL of 
competent cells were transformed with 50  ng of pFREE 
or pFREE-RK2 by electroporation (1.65  kV, 200  Ohm, 
25 μF) and recovered for 2 h in 500 μL SOC medium at 
30 °C and shaking (500 rpm). After recovery, 50 μL of the 
recovered cells were transferred to 10  mL LB medium 
with 0.2% l-rhamnose, 200  ng/mL aTc and 50  μg/mL 
kanamycin added. The cultures were plated on non-
selective LB agar after 24 h of incubation. 50 colonies of 
each replicate were checked on relevant antibiotics to 
assess the curing efficiency.
Assessment of genomic off‑target effects
Two parallel cultures were initiated from each of three 
individual colonies of E. coli carrying pFREE and P. 
putida carrying pFREE-RK2. One culture was induced 
to activate the curing process while the other functioned 
as a control without induction of pFREE. Both cultures 
were grown at 30  °C shaking (250  rpm) for 24  h and 
genomic DNA was purified using the QIAGEN blood 
and tissue DNA isolation kit. The genomic DNA was 
prepared for sequencing using the KAPA HyperPlus 
Kit (Kapa Biosystems) and the resulting libraries were 
sequenced on an Illumina NextSeq platform. Fastq out-
put files were imported into CLC Genomics Workbench 
software (QIAGEN) where all analysis was performed. 
Reads were trimmed and quality filtered before map-
ping of the reads, originating from the plasmid cured 
genomes, to the assembled control genomes. SNP and 
small INDEL variants were detected using quality based 
variant detection and larger INDELS and structural vari-
ants were assessed using the “Structural Variants and 
InDels” pipeline as well as by manual inspection of read 
mappings.
Additional file
Additional file 1. Supplementary information.
Authors’ contributions
IL, AP, MHHN and MOAS designed the experiments. IL and AP performed the 
experiments. IL and AP wrote the manuscript with input from MHHN and 
MOAS. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to acknowledge Pablo Ivan Nikel and Patricia Maria 
Calero Valdayo for providing the P. putida strain and plasmid.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All constructs are available from Addgene. Whole genome sequence data has 
been deposited in NCBI’s short read achieve and can be accessed from the 
Bioproject PRJNA393518.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This work was supported by the EU H2020 ERC-20104-STG LimitMDR (638902) 
Grant, the Danish Council for Independent Research Sapere Aude programme 
DFF-4004-00213 and the Novo Nordisk Foundation.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 10 May 2017   Accepted: 22 July 2017
References
 1. Cohen SN. DNA cloning: a personal view after 40 years. Proc Natl Acad Sci 
USA. 2013;110:15521–9.
 2. Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of bio-
logically functional bacterial plasmids in vitro. Proc Natl Acad Sci USA. 
1973;70:3240–4.
 3. Chang ACY, Cohen SN. Construction and characterization of amplifiable 
DNA cloning vectors derived from P15A cryptic plasmid. J Bacteriol. 
1978;134:1141–56.
 4. Chang ACY, Cohen SN. Genome construction between bacterial species 
in vitro: replication and expression of Staphylococcus plasmid genes in 
Escherichia coli. Proc Natl Acad Sci USA. 1974;71:1030–4.
 5. Hershfield V, Boyer HW, Yanofsky C, Lovett MA, Helinski DR. Plasmid ColEl 
as a molecular vehicle for cloning and amplification of DNA. Proc Natl 
Acad Sci USA. 1974;71:3455–9.
 6. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia 
coli: advances and challenges. Front Microbiol. 2014;5:1–17.
 7. Novick RP. Plasmid incompatibility. Microbiol Rev. 1987;51:381–95.
 8. Bolivar F, Rodriguez RL, Greene PJ, Betlach MC, Heyneker HL, Boyer HW, 
et al. Construction and characterization of new cloning vehicles. II. A 
multipurpose cloning system. Gene. 1977;2:95–113.
 9. Selzer G, Som T, Itoh T, Tomizawa JI. The origin of replication of plasmid 
p15A and comparative studies on the nucleotide sequences around the 
origin of related plasmids. Cell. 1983;32:119–29.
 10. del Solar G, Giraldo R, Ruiz-Echevarría MJ, Espinosa M, Díaz-Orejas R. Repli-
cation and control of circular bacterial plasmids. Microbiol Mol Biol Rev. 
1998;62:434–64.
 11. Jain A, Srivastava P. Broad host range plasmids. FEMS Microbiol Lett. 
2013;348:87–96.
 12. Tucker WT, Miller CA, Cohen SN. Structural and functional analysis of the 
par region of the pSC 101 plasmid. Cell. 1984;38:191–201.
Page 10 of 10Lauritsen et al. Microb Cell Fact  (2017) 16:135 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 13. Hale L, Lazos O, Haines AS, Thomas CM. An efficient stress-free strategy to 
displace stable bacterial plasmids. Biotechniques. 2010;48:223–8.
 14. Trevors J. Plasmid curing in bacteria. FEMS Microbiol Lett. 1986;32:149–57.
 15. Lee J, Saddler JN, Um Y, Woo HM. Adaptive evolution and metabolic engi-
neering of a cellobiose- and xylose- negative Corynebacterium glutami-
cum that co-utilizes cellobiose and xylose. Microb Cell Fact. 2016;15:20.
 16. Ginesy M, Belotserkovsky J, Enman J, Isaksson L, Rova U. Metabolic engi-
neering of Escherichia coli for enhanced arginine biosynthesis. Microb Cell 
Fact. 2015;14:29.
 17. Schlegel S, Genevaux P, de Gier JW. De-convoluting the genetic adapta-
tions of E. coli C41 (DE3) in real time reveals how alleviating protein 
production stress improves yields. Cell Rep. 2015;10:1758–66.
 18. Ronda C, Pedersen LE, Sommer MOA, Nielsen AT. CRMAGE: CRISPR 
optimized MAGE recombineering. Scientific Reports. Nature Publishing 
Group. 2016; 6:19452.
 19. Raman S, Rogers JK, Taylor ND, Church GM. Evolution-guided optimiza-
tion of biosynthetic pathways. Proc Natl Acad Sci. 2014;111:201409523.
 20. Kamruzzaman M, Shoma S, Thomas CM, Partridge SR, Iredell JR. Plasmid 
interference for curing antibiotic resistance plasmids in vivo. PLoS ONE. 
2017;12:e0172913.
 21. Crameri R, Davies JE, Hütter R. Plasmid curing and generation of muta-
tions induced with ethidium bromide in streptomycetes. J Gen Microbiol. 
1986;132:819–24.
 22. Hashimoto-Gotoh T, Franklin FCH, Nordheim A, Timmis KN. Specific-pur-
pose plasmid cloning vectors I. Low copy number, temperature-sensitive, 
mobilization-defective pSC101-derived containment vectors. Gene. 
1981;16:227–35.
 23. Reyrat J-M, Pelicic V, Gicquel B. Counterselectable markers: untapped 
tools for bacterial genetics and pathogenesis. Infect Immun. 
1998;66:4011–7.
 24. Gregg CJ, Lajoie MJ, Napolitano MG, Mosberg JA, Goodman DB, Aach J, 
et al. Rational optimization of tolC as a powerful dual selectable marker 
for genome engineering. Nucleic Acids Res. 2014;42:4779–90.
 25. Podolsky T, Fong S, Lee B. Direct selection of tetracycline-sensitive Escheri-
chia coli cells using nickel salts. Plasmid. 1996;115:112–5.
 26. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A pro-
grammable dual-RNA—guided DNA endonuclease in adaptive bacterial 
immunity. Science. 2012;337:816–22.
 27. Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing 
CRISPR-Cas9 technology. Gene. 2017;599:1–18 (Elsevier B. V.).
 28. Kim JS, Cho DH, Park M, Chung WJ, Shin D, Ko KS, et al. CRISPR/
Cas9-mediated re-sensitization of antibiotic-resistant Escherichia coli 
harboring extended-spectrum Beta-lactamases. J Microbiol Biotechnol. 
2015;26:394–401.
 29. Kamens J. The Addgene repository: an international nonprofit plasmid 
and data resource. Nucleic Acids Res. 2015;43:D1152–7.
 30. Lutz R, Bujard H. Independent and tight regulation of transcriptional units 
in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory 
elements. Nucleic Acids Res. 1997;25:1203–10.
 31. Silva-Rocha R, Martínez-García E, Calles B, Chavarría M, Arce-Rodríguez A, 
De Las Heras A, et al. The standard european vector architecture (SEVA): a 
coherent platform for the analysis and deployment of complex prokary-
otic phenotypes. Nucleic Acids Res. 2013;41:666–75.
 32. Karunakaran P, Blatny JM, Ertesvåg H, Valla S. Species-dependent pheno-
types of replication-temperature-sensitive trfA mutants of plasmid RK2: 
a codon-neutral base substitution stimulates temperature sensitivity by 
leading to reduced levels of trfA expression. J Bacteriol. 1998;180:3793–8.
 33. Haugan K, Karunakaran P, Blatny JM, Valla S. The phenotypes of temper-
ature-sensitive mini-RK2 replicons carrying mutations in the replication 
control gene trfA are suppressed nonspecifically by intragenic cop muta-
tions. J Bacteriol. 1992;174:7026–32.
 34. Nikel PI, Chavarría M, Danchin A, de Lorenzo V. From dirt to industrial 
applications: Pseudomonas putida as a synthetic biology chassis for host-
ing harsh biochemical reactions. Curr Opin Chem Biol. 2016;34:20–9.
 35. Schaefer KA, Wu W-H, Colgan DF, Tsang SH, Bassuk AG, Mahajan VB. 
Unexpected mutations after CRISPR–Cas9 editing in vivo. Nat Publ Gr. 
2017;14:547–8.
 36. Velappan N, Sblattero D, Chasteen L, Pavlik P, Bradbury ARM. Plasmid 
incompatibility: more compatible than previously thought? Protein Eng 
Des Sel. 2007;20:309–13.
 37. Nicoloff HH, Andersson DI. Indirect resistance to several classes of antibi-
otics in cocultures with resistant bacteria expressing antibiotic-modifying 
or -degrading enzymes. J Antimicrob Chemother. 2016;71:100–10.
 38. Lenski RE, Simpson SC, Nguyen TT. Genetic analysis of a plasmid-
encoded, host genotype-specific enhancement of bacterial fitness. J 
Bacteriol. 1994;176:3140–7.
 39. Li Y, Lin Z, Huang C, Zhang Y, Wang Z, Tang YJ, et al. Metabolic engineer-
ing of Escherichia coli using CRISPR-Cas9 mediated genome editing. 
Metab Eng. 2015;31:13–21 (Elsevier).
 40. Martínez-García E, Calles B, Arévalo-Rodríguez M, de Lorenzo V. pBAM1: 
an all-synthetic genetic tool for analysis and construction of complex 
bacterial phenotypes. BMC Microbiol. 2011;11:38.
 41. Stearns T, Ma H, Botstein D. Manipulating yeast genome using plasmid 
vectors. Methods Enzymol. 1990;185:280–97.
 42. Shintani M, Sanchez ZK, Kimbara K. Genomics of microbial plasmids: 
classification and identification based on replication and transfer systems 
and host taxonomy. Front Microbiol. 2015;6:1–16.
 43. Johnson TJ, Wannemuehler YM, Johnson SJ, Logue CM, White DG, 
Doetkott C, et al. Plasmid replicon typing of commensal and pathogenic 
Escherichia coli isolates. Appl Environ Microbiol. 2007;73:1976–83.
 44. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment 
search tool. J Mol Biol. 1990;215:403–10.
 45. Cavaleiro AM, Kim SH, Seppälä S, Nielsen MT, Nørholm MHH. Accurate 
DNA assembly and genome engineering with optimized uracil excision 
cloning. ACS Synth Biol. 2015;4:1042–6.
 46. Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO, 
et al. Enzymatic assembly of DNA molecules up to several hundred 
kilobases. Nat Methods. 2009;6:343–5.
 47. Datta S, Costantino N, Court DL. A set of recombineering plasmids for 
gram-negative bacteria. Gene. 2006;379:109–15.
 48. Nour-Eldin HH, Hansen BG, Nørholm MHH, Jensen JK, Halkier BA. Advanc-
ing uracil-excision based cloning towards an ideal technique for cloning 
PCR fragments. Nucleic Acids Res. 2006;34:e122.
